Your browser doesn't support javascript.
loading
Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient.
Fournier, Marie; Chen, Chieh-I; Kuznik, Andreas; Proudfoot, Clare; Mallya, Usha G; Michaud, Kaleb.
Affiliation
  • Fournier M; Health Economics & Value Assessment, Sanofi France, Chilly-Mazarin, France, Marie.Fournier@sanofi.com.
  • Chen CI; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Kuznik A; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Proudfoot C; Sanofi, Guildford, UK.
  • Mallya UG; Sanofi, Bridgewater, NJ, USA.
  • Michaud K; University of Nebraska Medical Center, Omaha, NE, USA.
Clinicoecon Outcomes Res ; 11: 117-128, 2019.
Article in En | MEDLINE | ID: mdl-30787625
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Language: En Journal: Clinicoecon Outcomes Res Year: 2019 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Language: En Journal: Clinicoecon Outcomes Res Year: 2019 Document type: Article